title: Hypersensitivity reaction caused by folinic acid administration: a case report and literature review.
abstract: 5-Fluorouracil (5-FU) is combined with folinic acid (FA) for enhancing its cytotoxic effects in the colon cancer chemotherapy treatment. Folinic acid has rarely been involved in hypersensitivity reactions. Here, we report a case of FA hypersensitivity in an adult patient initially attributed to oxaliplatin administered concurrently. A 56-year-old male patient diagnosed with colon cancer received twelve cycles of FOLFOX4, one cycle of FOLFIRI plus cetuximab and nine cycles of FOLFOX6 uneventful. At the tenth cycle of FOLFOX6 chemotherapy, after 15 minutes of starting the infusion of oxaliplatin and FA, the patient reported flushing, pruritus and abdominal pain and erythema and oedema developed over the face and thorax. After progression, FOLFIRI plus aflibercept was scheduled and another reaction occurred. At this time, FA was discontinued and the patient received another cycle consisted on irinotecan plus 5-FU without incidences. This episode of hypersensitivity reaction following FA infusion with no oxaliplatin empirically confirmed that the hypersensitivity reaction was secondary to FA. Clinicians should be aware of hypersensitivity reaction with FA, especially when FA is administered concomitantly with oxaliplatin, despite its lower risk to cause hypersensitivity reactions. Furthermore, the similar signs and symptoms associated to the hypersensitivity reactions of each agent, highlight the importance of having a specialised allergist team for to make a prompt diagnose of the causative agent in order to prevent patient harm and proceed properly without unnecessary delays in the scheduled chemotherapy treatments.
authors.affiliation: a Department of Pharmacy , Hospital Universitari del Mar , Barcelona , Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Florit-Sureda
authors.affiliation: a Department of Pharmacy , Hospital Universitari del Mar , Barcelona , Spain.|b IMIM (Instituto de Investigación Hospital del Mar) , Barcelona , Spain.
authors.forename: David
authors.initials: D
authors.lastname: Conde-Estévez
authors.affiliation: c Department of Medical Oncology , Hospital Universitari del Mar , Barcelona , Spain.
authors.forename: Joana
authors.initials: J
authors.lastname: Vidal
authors.affiliation: b IMIM (Instituto de Investigación Hospital del Mar) , Barcelona , Spain.|c Department of Medical Oncology , Hospital Universitari del Mar , Barcelona , Spain.
authors.forename: Clara
authors.initials: C
authors.lastname: Montagut
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000175:diagnosis; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
keywords: Chemotherapy; Colon cancer; Folinic acid; Hypersensitivity reaction